Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025 - PubMed
4 hours ago
- #breast cancer
- #CDK4/6 inhibitors
- #endocrine therapy
- HR+/HER2- early breast cancer (EBC) is the most common subtype and is biologically diverse.
- Endocrine therapy (ET) is the foundation of treatment, with chemotherapy, CDK4/6 inhibitors, and bone-modifying agents tailored to tumor biology, stage, and menopausal status.
- The REAL Canadian Breast Cancer Alliance developed 28 consensus recommendations for systemic management.
- Key recommendations include selective neoadjuvant chemotherapy for high-risk or locally advanced disease and genomic testing to guide chemotherapy decisions, especially in postmenopausal patients.
- Adjuvant therapy should include ET, with CDK4/6 inhibitors for higher-risk patients and bisphosphonates for postmenopausal women to reduce recurrence and improve survival.
- The recommendations aim to support individualized, patient-centered care in Canada.